Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* IUGR defined as birth length and/or weight below the lower limit (\< P10) of the Lubchenco curves for the gestational age.~* Chronological age = 2-5 years~* HV below average for CA~* Insufficient catch-up growth (Height \< P3 for chronological age, according to Hernández)~* Parental height greater than or equal to -2 SDS of average, that is, 160 cm or more for the father and 148 cm or more for the mother~* Normal response to GH stimulation test (greater tan or equal to 10 ng/mL)~* Bone age (measured through Greulich and Pyle method) less than or equal to CA~Exclusion Criteria:~* Children born from multiple pregnancy~* Children with post-ischemic encephalopathy~* Recorded malformative syndromes associated to short stature (Silver-Russell, Rubinstein Taybi, Seckel etc.)~* Any metabolic or endocrinological disorder (diabetes mellitus, diabetes insipidus, congenital metabolic disorders, with the exception of thyroid diseases corrected by replacement therapy)~* Any type of growth retardation associated to infections, embryopathies or severe chronic diseases (hemopathies, hepatopathies, malabsorptive pathology, neurologic alterations....)~* Nutritional disorders (celiac disease) or osteodystrophies~* Patients who receive or received any treatment (anabolic drugs, sex steroids, etc.) likely to interfere with GH effects~* Abnormal karyotype~* Neoplasms~* Previous or ongoing chemotherapy and/or irradiation~* Renal dysfunction, defined as serum creatinine \> 1 mg/dL

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).